Ozempic reduces knee osteoarthritis pain by almost half: Study
The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain among patients with knee osteoarthritis and obesity.
The study funded by Novo Nordisk, the manufacturer of Ozempic and Wegovy, involved 407 participants taking either the active ingredient semaglutide or a placebo for 68 weeks. Roughly 82 percent of participants were women.
To measure pain, researchers used the Western Ontario and McMaster Universities Arthritis Index (WOMAC). The WOMAC involves participants scoring pain, difficulty and physical function when doing everyday activities like walking up and down stairs or sitting.
At the start of the trial, the average WOMAC pain score among participants was 70.9. By the 68th week, those taking semaglutide reported an average WOMAC pain score of 29.2, while those taking a placebo reported an average pain score of 43.4.
The semaglutide participants on average had a body weight reduction of 13.7 percent, while those taking a placebo had a 3.2 percent reduction on average.
"Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo," the study's conclusion stated.
As the Johns Hopkins Arthritis Center notes, overweight women have almost four times the risk of developing knee osteoarthritis when compared to non-obese women. For obese men, the risk is five times higher than their non-obese counterparts.
GLP-1 agonists like semaglutide have been explored for uses beyond obesity and diabetes. Semaglutide has been studied for potential benefits for treating addiction, kidney failure, liver disease and early Alzheimer’s disease.
Topics
-
Ozempic and Wegovy Ease Knee Osteoarthritis Pain in Large Study
Health - The New York Times - November 1 -
Semaglutide linked to reduced arthritis knee pain in people with obesity, study finds
Top stories - NBC News - October 30 -
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
Business - CNBC - October 24 -
Ozempic can lead to muscle mass loss: Study
Politics - The Hill - November 9 -
Ozempic and Wegovy may be beneficial in fighting alcohol addiction: Study
Politics - The Hill - November 14 -
Almost half of Valencia’s flood victims were aged over 70, figures show
World - The Guardian - 6 days ago -
Rocky Knockout Collection Is Almost Half Off For Black Friday
Tech - GameSpot - 4 hours ago -
Climate crisis caused half of European heat deaths in 2022, says study
World - The Guardian - October 29
More from The Hill
-
Bill O'Reilly: Donald Trump Cabinet will have zero policy input
Politics - The Hill - 6 minutes ago -
Will DOGE put spending on the chopping block?
Politics - The Hill - 12 minutes ago -
Stephen A. Smith: Trump may have ulterior motive for Gaetz pick
Politics - The Hill - 16 minutes ago -
What RFK Jr. could — and couldn't — do with vaccines as HHS chief
Politics - The Hill - 26 minutes ago -
World War III is now Trump's to lose
Politics - The Hill - 42 minutes ago